Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

Diabetologia

Volumn 48, Issue 6, 2005, Pages 1168-1172

  Mannucci, E ^a   Pala, L ^a   Ciani, S ^a   Bardini, G ^a   Pezzatini, A ^a   Sposato, I ^b   Cremasco, F ^a   Ognibene, A ^b   Rotella, C M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Diabetes mellitus; Dipeptidyl peptidase IV

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C;

ADULT; ARTICLE; BLOOD ANALYSIS; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; ENZYME ACTIVITY; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL;

ADULT; AGED; ANTIGENS, CD26; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; LONGITUDINAL STUDIES; MALE; REFERENCE VALUES; REGRESSION ANALYSIS;

EID: 21344451403     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1749-8     Document Type: Article

References (23)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1304
2. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW (1994) Glucagon-like peptide-1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 95:2263-2266
3. Gutzwiller JP, Goke B, Drewe J et al (1999) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44:81-86
4. Lugari R, Dell'Anna C, Ugolotti D et al (2000) Effect of nutrient ingestion on glucagon-like peptide-1 (7-36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res 32:424-428
5. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentration of intact biologically active glucagon-like peptide-1 in type 2 diabetic patients. Diabetes 50:609-613
6. Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB (1996) Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM) - evidence for decreased glucagon-like peptide-1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135:425-432
7. Mannucci E, Ognibene A, Cremasco F et al (2000) Glucagon-like peptide-1 (GLP-1) and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabet Med 17:713-719
8. Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723
9. Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M (1998) Exendin (9-39) is an antagonist of glucagon-like peptide-1 (7-36) amide in humans. J Clin Invest 101:1421-1430
10. Edwards CM, Todd JF, Mahmoudi M et al (1999) Glucagon-like peptide-1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48:86-93
11. Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1-(7-36) amide, peptide histidine methionine, and is responsible for their degradation in human serum. Eur J Biochem 214:829-835
12. Berghofer P, Peterson RG, Schneider K, Fehmann HC, Goke B (1997) Incretin hormone expression in the gut of diabetic mice and rats. Metabolism 46:261-267
13. Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220-224
14. Meneilly GS, Demuth HU, McIntosh CH, Pederson RA (2000) Effect of ageing and diabetes on glucose-dependent insulin-otropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 17:346-350
15. Pala L, Mannucci E, Pezzatini A et al (2003) Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 310:28-31
16. Mannucci E, Ognibene A, Sposato I et al (2003) Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 40:181-186
17. Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpe S, De Meester I (2001) Reference values for plasma dipeptidylpeptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med 39:155-158
18. Augustyns K, Bal G, Thonus G et al (1999) The unique properties of dipeptidyl-peptidase IV (DPP IV/CD 26) and the therapeutic potential of DPP-IV inhibitors. Curr Med Chem 6:311-327
19. Mannucci E, Ognibene A, Cremasco F et al (2001) Effects of metformin on glucagon-like peptide-1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care 24:489-494
20. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ (2000) Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581
21. Rosenblum JF, Kozarich JW (2003) Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 7:496-504
22. Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Flatt PR, O'Harte FP (2004) Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase-IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin(9-39). Metabolism 53:252-259
23. Wettergren A, Wojdemann M, Holst JJ (1998) The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 19:877-892